For many years, Alzheimer’s disease research was completely stifled by a lack of funding. Pharmaceutical companies were too wary of past failures to fund any new drug development. The drug pipeline was coming up dry, and researchers weren’t encouraged to think big or bold.
Leveraging their experience in venture capital and corporate start-ups, our founders – Henry McCance, Phyllis Rappaport, and Jacqui and Jeff Morby – came together to build a new Alzheimer’s research fund designed to dramatically accelerate research, make bold bets and focus exclusively on finding a cure.
Since its founding, Cure Alzheimer’s Fund has contributed more than $50,000,000 to research, and its funded initiatives have been responsible for several key breakthroughs—including the ground-breaking “Alzheimer’s in a Dish”, which promises to greatly accelerate drug testing and was reported by The New York Times as a “giant step forward”.
Cure Alzheimer’s Fund supports the best scientific minds in the field of Alzheimer’s research, and it does so without any financial gain for its founders or donors. Fully 100 percent of funds raised by Cure Alzheimer’s Fund go directly to research—the Board of Directors covers all overhead expenses. Our Research Consortium is an all-star team of scientists working at premier institutions around the world, regularly conferring with one another on the progress and impediments in their research and constantly sharing their data.